Daiichi Sankyo Company, Limited

The University of Tokyo

Yoshito Hamada

Jun Watanabe

Osamu Kanno

Daisuke Honma

Nobuaki Adachi

Keisuke Suzuki

Kenji Yoshikawa

Akira Nakao

Yuko Yamamoto

Yoshiko Kagoshima

Yasuyuki Takeda

Takao Horiuchi

Yuichi Tominaga

Ryoichi Tanaka

Masaki Kiga

Tomonori Yamasaki

Makoto Yamagishi

Toshiki Watanabe

The present invention provides a compound having a particular chemical structure or a pharmacologically acceptable salt thereof which has an excellent inhibitory effect on EZH1 and/or EZH2 activity. The present invention provides a compound having a 1, 3-benzodioxole structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, or a pharmaceutical composition comprising the compound (wherein R, R, R, R, R, R, and V in the formula (I) are each as defined in the present specification). 

1,3-benzodioxole derivative

The present invention provides an agent for treating and/or preventing adult T cell leukemia/lymphoma containing a compound having a specific chemical structure or a pharmaceutically acceptable salt thereof. Specifically, the present invention provides an agent for treating and/or preventing adult T cell leukemia/lymphoma containing, as an active ingredient, 7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide or a pharmaceutically acceptable salt thereof, or 7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide or a pharmaceutically acceptable salt thereof.

Agent for treating and/or preventing adult T cell leukemia/lymphoma

The present invention provides a compound having a particular chemical structure or a pharmacologically acceptable salt thereof which has an excellent inhibitory effect on EZH1 and/or EZH2 activity. The present invention provides a compound having a 1,3-benzodioxole structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, or a pharmaceutical composition comprising the compound (wherein R, R, R, R, R, R, and V in the formula (I) are each as defined in the present specification). 

The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R, G, T, Y, Y, Y, and Yare as defined herein.

Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors

Growing community of inventors

Tokyo, Japan

Yoshito Hamada